Altimmune Regains Some Momentum

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.  

Newton's Cradle Momentum
• Source: Leigh Prather / Alamy Stock Photo

Updated results of the Phase II MOMENTUM trial of Altimmune Inc.’s obesity candidate pemvidutide have allowed the company to regain some of the ground it lost in March when an earlier cut from the same study revealed worryingly high discontinuations.

Key Takeaways
  • Updated data on Altimmune’s GLP-1/glucagon co-agonist pemvidutide are better than an earlier cut

The new data reveal improved efficacy and lower discontinuations, and Altimmune’s shares opened up by 83% at $5.80 on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D